Twist Bioscience (TWST) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

TWST Stock Forecast

Twist Bioscience stock forecast is as follows: an average price target of $46.00 (represents a -1.01% downside from TWST’s last price of $46.47) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

TWST Price Target

The average price target for Twist Bioscience (TWST) is $46.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $46.00. This represents a potential -1.01% downside from TWST's last price of $46.47.

TWST Analyst Ratings

Buy

According to 7 Wall Street analysts, Twist Bioscience's rating consensus is 'Buy'. The analyst rating breakdown for TWST stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Twist Bioscience Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 17, 2024	Catherine Schulte	Robert W. Baird	$46.00	$48.18	-4.52%	-1.01%
Jun 05, 2024	Subbu Nambi	Guggenheim	$53.00	$46.98	12.81%	14.05%
May 03, 2024	Catherine Ramsey Schulte	Robert W. Baird	$40.00	$32.01	24.96%	-13.92%
Jan 17, 2024	Matthew Sykes	Goldman Sachs	$45.00	$34.84	29.16%	-3.16%
Feb 05, 2023	Luke Sergott	Barclays	$32.00	$25.31	26.43%	-31.14%
Jan 03, 2023		Evercore ISI	$36.00	$24.73	45.60%	-22.53%
Oct 06, 2022	Luke Sergott	Barclays	$45.00	$38.51	16.85%	-3.16%

The latest Twist Bioscience stock forecast, released on Sep 17, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $46.00, which represents a -4.52% decrease from the stock price at the time of the forecast ($48.18), and a -1.01% decrease from TWST last price ($46.47).

Twist Bioscience Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$46.00
Last Closing Price	$46.47	$46.47	$46.47
Upside/Downside	-100.00%	-100.00%	-1.01%

In the current month, the average price target of Twist Bioscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Twist Bioscience's last price of $46.47. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 18, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 01, 2024	Evercore ISI	Outperform	Outperform	Hold
Aug 06, 2024	Scotiabank	Outperform	Outperform	Hold
Jun 28, 2024	Barclays	Overweight	Overweight	Hold
Jun 13, 2024	Cowen & Co.	Buy	Buy	Hold
Jun 04, 2024	Barclays	Overweight	Overweight	Hold
Jun 04, 2024	Guggenheim		Buy	Initialise
May 06, 2024	Scotiabank	Outperform	Outperform	Hold
May 03, 2024	Evercore ISI	Outperform	Outperform	Hold
May 03, 2024	William Blair	Outperform	Outperform	Hold
May 03, 2024	Barclays	Overweight	Overweight	Hold
Jan 17, 2024	Goldman Sachs	Neutral	Buy	Upgrade
Apr 18, 2023	Goldman Sachs	Neutral	Neutral	Hold
Feb 05, 2023	Barclays	Overweight	Overweight	Hold
Jan 05, 2023	Scotiabank		Sector Outperform	Initialise
Jan 03, 2023	Evercore ISI		Outperform	Upgrade
Oct 06, 2022	Barclays	Overweight	Overweight	Hold

Twist Bioscience's last stock rating was published by Cowen & Co. on Nov 18, 2024. The company gave TWST a "Buy" rating, the same as its previous rate.

Twist Bioscience Financial Forecast

Twist Bioscience Revenue Forecast

	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	$71.50M	$66.95M	$63.74M	$60.18M	$54.24M	$57.31M	$56.11M	$48.13M	$42.02M	$37.95M	$35.02M	$31.20M	$28.16M	$32.43M	$21.21M	$19.30M	$17.16M	$15.74M	$13.60M
Avg Forecast	$116.99M	$112.49M	$105.67M	$101.88M	$99.75M	$95.71M	$90.87M	$86.97M	$82.71M	$77.40M	$70.70M	$67.59M	$63.35M	$60.62M	$56.64M	$54.41M	$56.90M	$52.06M	$45.26M	$38.63M	$36.60M	$32.42M	$28.32M	$26.10M	$22.95M	$14.18M	$18.28M	$16.22M	$14.05M	$12.77M
High Forecast	$118.29M	$113.74M	$106.84M	$103.01M	$100.85M	$96.77M	$91.64M	$87.13M	$82.89M	$77.40M	$70.71M	$68.34M	$63.74M	$61.29M	$57.27M	$54.85M	$56.90M	$52.06M	$45.26M	$38.63M	$36.60M	$32.42M	$28.32M	$26.10M	$22.95M	$14.18M	$18.28M	$16.22M	$14.05M	$12.77M
Low Forecast	$115.70M	$111.25M	$104.50M	$100.76M	$98.65M	$94.65M	$90.26M	$86.80M	$82.54M	$77.40M	$70.69M	$66.84M	$62.90M	$59.95M	$56.02M	$53.97M	$56.90M	$52.06M	$45.26M	$38.63M	$36.60M	$32.42M	$28.32M	$26.10M	$22.95M	$14.18M	$18.28M	$16.22M	$14.05M	$12.77M
# Analysts	3	3	3	4	4	4	6	6	3	3	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.06%	1.06%	1.05%	1.06%	1.00%	1.01%	1.08%	1.06%	1.09%	1.04%	1.08%	1.10%	1.08%	1.41%	1.50%	1.06%	1.06%	1.12%	1.06%

Twist Bioscience's average Quarter revenue forecast for Mar 24 based on 4 analysts is $70.70M, with a low forecast of $70.69M, and a high forecast of $70.71M. TWST's average Quarter revenue forecast represents a -1.11% decrease compared to the company's last Quarter revenue of $71.50M (Dec 23).

Twist Bioscience EBITDA Forecast

	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	3	3	3	4	4	4	6	6	3	3	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-46.98M	$-42.97M	$-44.68M	$-59.67M	$-45.88M	$-56.58M	$-64.90M	$-62.83M	$-52.79M	$-38.39M	$-35.02M	$-35.30M	$2.15M	$-22.02M	$-26.28M	$-29.93M	$-53.85M	$-29.29M	$-25.96M
Avg Forecast	$-98.65M	$-94.86M	$-89.10M	$-85.91M	$-84.11M	$-80.70M	$-76.62M	$-73.33M	$-69.74M	$-65.27M	$-76.41M	$-56.99M	$-53.42M	$-51.12M	$-69.46M	$-66.29M	$-54.49M	$-49.86M	$-63.15M	$-37.00M	$-35.05M	$-31.05M	$-34.84M	$-25.00M	$-21.98M	$-13.57M	$-25.94M	$-15.53M	$-13.45M	$-12.23M
High Forecast	$-97.56M	$-93.81M	$-88.12M	$-84.96M	$-83.18M	$-79.81M	$-76.11M	$-73.19M	$-69.60M	$-65.27M	$-61.13M	$-56.36M	$-53.04M	$-50.55M	$-55.57M	$-53.03M	$-54.49M	$-49.86M	$-50.52M	$-37.00M	$-35.05M	$-31.05M	$-27.87M	$-25.00M	$-21.98M	$-13.57M	$-20.75M	$-15.53M	$-13.45M	$-12.23M
Low Forecast	$-99.74M	$-95.91M	$-90.09M	$-86.86M	$-85.04M	$-81.60M	$-77.27M	$-73.47M	$-69.89M	$-65.27M	$-91.69M	$-57.62M	$-53.75M	$-51.68M	$-83.35M	$-79.55M	$-54.49M	$-49.86M	$-75.77M	$-37.00M	$-35.05M	$-31.05M	$-41.81M	$-25.00M	$-21.98M	$-13.57M	$-31.13M	$-15.53M	$-13.45M	$-12.23M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.82%	0.80%	0.87%	0.86%	0.69%	1.04%	1.30%	1.00%	1.43%	1.10%	1.13%	1.01%	-0.09%	1.00%	1.94%	1.15%	3.47%	2.18%	2.12%

4 analysts predict TWST's average Quarter EBITDA for Mar 21 to be $-34.84M, with a high of $-27.87M and a low of $-41.81M. This is -1720.35% lower than Twist Bioscience's previous annual EBITDA (Dec 20) of $2.15M.

Twist Bioscience Net Income Forecast

	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	3	3	3	4	4	4	6	6	3	3	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-43.01M	$-46.24M	$-57.40M	$-59.16M	$-41.82M	$-51.12M	$-60.52M	$-60.67M	$-45.56M	$-41.24M	$-40.04M	$-37.92M	$-32.81K	$-24.32M	$-28.21M	$-31.77M	$-55.64M	$-31.18M	$-27.92M
Avg Forecast	$-24.35M	$-26.24M	$-28.40M	$-29.49M	$-28.95M	$-32.28M	$-35.44M	$-36.71M	$-41.80M	$-44.73M	$-82.01M	$-45.48M	$-53.80M	$-65.86M	$-74.56M	$-57.21M	$-72.61M	$-75.04M	$-67.78M	$-61.85M	$-46.66M	$-43.54M	$-37.43M	$-40.93M	$-40.29M	$-40.85M	$-27.53M	$-63.61M	$-48.55M	$-47.53M
High Forecast	$-24.00M	$-25.87M	$-27.99M	$-29.07M	$-28.53M	$-31.82M	$-33.67M	$-34.34M	$-41.20M	$-44.09M	$-65.61M	$-44.82M	$-46.79M	$-64.92M	$-59.64M	$-45.77M	$-72.61M	$-75.04M	$-54.22M	$-61.85M	$-46.66M	$-43.54M	$-29.94M	$-40.93M	$-40.29M	$-40.85M	$-22.03M	$-63.61M	$-48.55M	$-47.53M
Low Forecast	$-24.70M	$-26.62M	$-28.81M	$-29.91M	$-29.37M	$-32.75M	$-36.62M	$-38.49M	$-42.40M	$-45.38M	$-98.41M	$-46.13M	$-73.10M	$-66.81M	$-89.47M	$-68.65M	$-72.61M	$-75.04M	$-81.33M	$-61.85M	$-46.66M	$-43.54M	$-44.91M	$-40.93M	$-40.29M	$-40.85M	$-33.04M	$-63.61M	$-48.55M	$-47.53M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.95%	0.86%	0.87%	0.79%	0.73%	0.70%	0.81%	0.90%	0.74%	0.88%	0.92%	1.01%	0.00%	0.60%	0.69%	1.15%	0.87%	0.64%	0.59%

Twist Bioscience's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TWST's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Twist Bioscience SG&A Forecast

	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	3	3	3	4	4	4	6	6	3	3	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	$52.84M	$47.39M	$46.06M	$53.97M	$42.32M	$54.16M	$53.69M	$54.00M	$51.10M	$38.24M	$34.48M	$34.39M	$46.95M	$27.18M	$22.49M	$27.19M	$26.41M	$24.42M	$21.32M
Avg Forecast	$109.76M	$105.54M	$99.14M	$95.59M	$93.58M	$89.79M	$85.26M	$81.59M	$77.60M	$72.62M	$66.33M	$63.41M	$59.44M	$56.87M	$53.14M	$51.05M	$62.21M	$56.92M	$49.48M	$42.24M	$40.01M	$35.44M	$30.97M	$28.54M	$25.09M	$15.50M	$19.99M	$17.74M	$15.36M	$13.96M
High Forecast	$110.98M	$106.72M	$100.24M	$96.65M	$94.62M	$90.79M	$85.98M	$81.74M	$77.77M	$72.62M	$66.34M	$64.12M	$59.80M	$57.51M	$53.73M	$51.46M	$62.21M	$56.92M	$49.48M	$42.24M	$40.01M	$35.44M	$30.97M	$28.54M	$25.09M	$15.50M	$19.99M	$17.74M	$15.36M	$13.96M
Low Forecast	$108.55M	$104.38M	$98.05M	$94.53M	$92.55M	$88.80M	$84.68M	$81.43M	$77.44M	$72.62M	$66.33M	$62.71M	$59.01M	$56.25M	$52.56M	$50.63M	$62.21M	$56.92M	$49.48M	$42.24M	$40.01M	$35.44M	$30.97M	$28.54M	$25.09M	$15.50M	$19.99M	$17.74M	$15.36M	$13.96M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.83%	0.80%	0.81%	1.02%	0.83%	0.87%	0.94%	1.09%	1.21%	0.96%	0.97%	1.11%	1.65%	1.08%	1.45%	1.36%	1.49%	1.59%	1.53%

Twist Bioscience's average Quarter SG&A projection for Mar 24 is $66.33M, based on 4 Wall Street analysts, with a range of $66.33M to $66.34M. The forecast indicates a 25.54% rise compared to TWST last annual SG&A of $52.84M (Dec 23).

Twist Bioscience EPS Forecast

	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	3	3	3	4	4	4	6	6	3	3	4	5	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	4
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.75	$-0.81	$-1.01	$-1.04	$-0.74	$-0.91	$-1.08	$-1.13	$-0.91	$-0.84	$-0.82	$-0.78	$-0.00	$-0.54	$-0.67	$-0.85	$-1.69	$-0.96	$-0.92
Avg Forecast	$-0.42	$-0.45	$-0.49	$-0.50	$-0.49	$-0.55	$-0.61	$-0.63	$-0.71	$-0.76	$-0.82	$-0.78	$-0.92	$-1.12	$-1.13	$-1.13	$-1.25	$-1.29	$-1.23	$-1.06	$-0.80	$-0.75	$-0.76	$-0.70	$-0.69	$-0.70	$-0.76	$-1.09	$-0.83	$-0.82
High Forecast	$-0.41	$-0.44	$-0.48	$-0.50	$-0.49	$-0.54	$-0.57	$-0.59	$-0.70	$-0.75	$-0.80	$-0.77	$-0.80	$-1.11	$-1.11	$-1.12	$-1.25	$-1.29	$-1.23	$-1.06	$-0.80	$-0.75	$-0.76	$-0.70	$-0.69	$-0.70	$-0.76	$-1.09	$-0.83	$-0.82
Low Forecast	$-0.42	$-0.45	$-0.49	$-0.51	$-0.50	$-0.56	$-0.63	$-0.66	$-0.72	$-0.77	$-0.83	$-0.79	$-1.25	$-1.14	$-1.14	$-1.15	$-1.25	$-1.29	$-1.23	$-1.06	$-0.80	$-0.75	$-0.76	$-0.70	$-0.69	$-0.70	$-0.76	$-1.09	$-0.83	$-0.82
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.97%	0.88%	0.90%	0.92%	0.65%	0.73%	0.84%	0.92%	0.86%	1.05%	1.10%	1.02%	0.00%	0.78%	0.95%	1.13%	1.54%	1.15%	1.13%

According to undefined Wall Street analysts, Twist Bioscience's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TWST previous annual EPS of $NaN (undefined).

Twist Bioscience Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CDNA	CareDx	$21.41	$37.50	75.15%	Buy
ICLR	ICON Public	$209.71	$337.00	60.70%	Buy
CSTL	Castle Biosciences	$26.65	$40.50	51.97%	Buy
EXAS	Exact Sciences	$56.19	$78.67	40.01%	Buy
GH	Guardant Health	$30.55	$41.75	36.66%	Buy
IQV	IQVIA	$196.51	$252.80	28.64%	Buy
PSNL	Personalis	$5.78	$7.38	27.68%	Buy
DHR	Danaher	$229.55	$289.50	26.12%	Buy
TMO	Thermo Fisher Scientific	$520.23	$640.88	23.19%	Buy
MTD	Mettler-Toledo	$1.22K	$1.41K	15.43%	Hold
ILMN	Illumina	$133.63	$147.78	10.59%	Buy
A	Agilent	$134.34	$147.40	9.72%	Buy
TWST	Twist Bioscience	$46.47	$46.00	-1.01%	Buy
NTRA	Natera	$158.30	$154.80	-2.21%	Buy
WAT	Waters	$370.98	$356.80	-3.82%	Buy

TWST Forecast FAQ

Is Twist Bioscience a good buy?

Yes, according to 7 Wall Street analysts, Twist Bioscience (TWST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of TWST's total ratings.

What is TWST's price target?

Twist Bioscience (TWST) average price target is $46 with a range of $46 to $46, implying a -1.01% from its last price of $46.47. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Twist Bioscience stock go up soon?

According to Wall Street analysts' prediction for TWST stock, the company can go down by -1.01% (from the last price of $46.47 to the average price target of $46), down by -1.01% based on the highest stock price target, and down by -1.01% based on the lowest stock price target.

Can Twist Bioscience stock reach $70?

TWST's average twelve months analyst stock price target of $46 does not support the claim that Twist Bioscience can reach $70 in the near future.

What are Twist Bioscience's analysts' financial forecasts?

Twist Bioscience's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $373.29M (high $376.39M, low $370.35M), average EBITDA is $-315M (high $-312M, low $-317M), average net income is $-133M (high $-128M, low $-137M), average SG&A $350.23M (high $353.14M, low $347.47M), and average EPS is $-2.278 (high $-2.192, low $-2.344). TWST's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $437.03M (high $441.88M, low $432.21M), average EBITDA is $-369M (high $-364M, low $-373M), average net income is $-108M (high $-107M, low $-110M), average SG&A $410.03M (high $414.59M, low $405.51M), and average EPS is $-1.853 (high $-1.826, low $-1.879).

Did the TWST's actual financial results beat the analysts' financial forecasts?

Based on Twist Bioscience's last annual report (Sep 2023), the company's revenue was $245.11M, beating the average analysts forecast of $235.02M by 4.29%. Apple's EBITDA was $-193M, missing the average prediction of $-240M by -19.59%. The company's net income was $-205M, missing the average estimation of $-251M by -18.62%. Apple's SG&A was $189.74M, missing the average forecast of $220.5M by -13.95%. Lastly, the company's EPS was $-3.6, missing the average prediction of $-4.303 by -16.34%. In terms of the last quarterly report (Dec 2023), Twist Bioscience's revenue was $71.5M, beating the average analysts' forecast of $67.59M by 5.78%. The company's EBITDA was $-46.977M, missing the average prediction of $-56.992M by -17.57%. Twist Bioscience's net income was $-43.008M, missing the average estimation of $-45.477M by -5.43%. The company's SG&A was $52.84M, missing the average forecast of $63.41M by -16.67%. Lastly, the company's EPS was $-0.75, missing the average prediction of $-0.777 by -3.43%